Journal of Medicinal Chemistry p. 6549 - 6560 (2006)
Update date:2022-07-30
Topics:
Chu, Xin-Jie
DePinto, Wanda
Bartkovitz, David
So, Sung-Sau
Vu, Binh T.
Packman, Kathryn
Lukacs, Christine
Ding, Qingjie
Jiang, Nan
Wang, Ka
Goelzer, Petra
Yin, Xuefeng
Smith, Melissa A.
Higgins, Brian X.
Chen, Yingsi
Xiang, Qing
Moliterni, John
Kaplan, Gerald
Graves, Bradford
Lovey, Allen
Fotouhi, Nader
The cyclin-dependent kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. Since deregulation of CDKs is found with high frequency in many human cancer cells, pharmacological inhibition of CDKs with small molecules has the potential to provide an effective strategy for the treatment of cancer. The 2,4-diamino-5-ketopyrimidines 6 reported here represent a novel class of potent and ATP-competitive inhibitors that selectively target the cyclin-dependent kinase family. This diaminopyrimidine core with a substituted 4-piperidine moiety on the C2-amino position and 2-methoxybenzoyl at the C5 position has been identified as the critical structure responsible for the CDK inhibitory activity. Further optimization has led to a good number of analogues that show potent inhibitory activities against CDK1, CDK2, and CDK4 but are inactive against a large panel of serine/threonine and tyrosine kinases (Ki > 10 μM). As one of these representative analogues, compound 39 (R547) has the best CDK inhibitory activities (Ki = 0.001, 0.003, and 0.001 μM for CDK1, CDK2, and CDK4, respectively) and excellent in vitro cellular potency, inhibiting the growth of various human tumor cell lines including an HCT116 cell line (IC50 = 0.08 μM). An X-ray crystal structure of 39 bound to CDK2 has been determined in this study, revealing a binding mode that is consistent with our SAR. Compound 39 demonstrates significant in vivo efficacy in the HCT116 human colorectal tumor xenograft model in nude mice with up to 95% tumor growth inhibition. On the basis of its superior overall profile, 39 was chosen for further evaluation and has progressed into Phase I clinical trial for the treatment of cancer.
View MoreShanghai Witshoot Internet Technology Co Ltd
Contact:+86-21-66390020
Address:Room 419, No.285 Luochuan Road (E)
website:http://www.herbpurify.com
Contact:0086-028-85249238
Address:Room709-C1,Incubator Building, Tianfu Life Science Park No.88,Keyuan Road,Gaoxin district,Chengdu City,Sichuan Prov,China
Xinchang Jiu Xin Pharmaceutical Co., Ltd
website:http://www.jiuxinpharm.com
Contact:86 137 5756 8585
Address:Poyang industry Park
SHANDONG QINGYUNCHANGXIN CHEMICAL SCIENCE-TECH CO.,LTD
Contact:86-21-60560171
Address:1689Donghuan Rade,Qingyun County, Dezhou City, Shandong,China
Weifang Yukai Chemical Co.,Ltd.
website:http://www.yukaichem.com/en.html
Contact:+86-536-8865336
Address:binhai economic development zone,262737 shangdong,china
Doi:10.1021/ol0491078
(2004)Doi:10.1016/S0020-1693(00)88343-7
(1981)Doi:10.1002/chem.201002577
(2010)Doi:10.1021/jm00183a001
(1980)Doi:10.1021/ja01344a049
(1932)Doi:10.1139/v63-218
()